Should I buy or sell Lantern Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LTRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LTRN, but not buy additional shares or sell existing shares. View LTRN analyst ratings or view top-rated stocks .

How have LTRN shares performed in 2024?

Lantern Pharma's stock was trading at $4.28 at the start of the year. Since then, LTRN stock has increased by 26.6% and is now trading at $5.42. View the best growth stocks for 2024 here .

Are investors shorting Lantern Pharma?

Lantern Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 420,900 shares, an increase of 191.1% from the March 15th total of 144,600 shares. Based on an average daily volume of 276,000 shares, the short-interest ratio is presently 1.5 days. Currently, 5.3% of the company's shares are sold short. View Lantern Pharma's Short Interest .

When is Lantern Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LTRN earnings forecast .

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01.

What ETF holds Lantern Pharma's stock?

Horizon Kinetics Medical ETF holds 28,791 shares of LTRN stock, representing 1.31% of its portfolio.

What other stocks do shareholders of Lantern Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT) , ARK Next Generation Internation ETF (ARKW) , Conagra Brands (CAG) , FedEx (FDX) , Lowe's Companies (LOW) , PayPal (PYPL) , Block (SQ) , Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK) .

When did Lantern Pharma IPO?

Lantern Pharma (LTRN) raised $26 million in an initial public offering on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

Who are Lantern Pharma's major shareholders?

Lantern Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pathway Financial Advisors LLC (0.23%). Insiders that own company stock include Aaron GL Fletcher and Leslie W Kreis. View institutional ownership trends .

How do I buy shares of Lantern Pharma?

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LTRN

Lantern Pharma (LTRN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free LTRN Stock Alerts

$5.35

-0.42 (-7.28%)

(As of 03:33 PM ET)

Compare

Today's Range: $5.20
▼
$5.65
50-Day Range: $3.87
▼
$10.65
52-Week Range: $2.38
▼
$11.99

Volume: 190,637 shs
Average Volume: 259,028 shs
Market Capitalization: $57.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Lantern Pharma alerts:

Lantern Pharma MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
5.33% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Selling Shares
$360,340 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.02) to ($1.91) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.04 out of 5 stars

Medical Sector

903rd out of 918 stocks

Pharmaceutical Preparations Industry

411th out of 419 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Lantern Pharma.

2.0

Short Interest

Percentage of Shares Shorted
5.33% of the float of Lantern Pharma has been sold short.
Short Interest Ratio / Days to Cover
Lantern Pharma has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lantern Pharma has recently increased by 191.08%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lantern Pharma does not currently pay a dividend.
Dividend Growth
Lantern Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LTRN.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Lantern Pharma this week, compared to 1 article on an average week.
Search Interest
Only 18 people have searched for LTRN on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
11 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lantern Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $360,340.00 in company stock.
Percentage Held by Insiders
Only 6.92% of the stock of Lantern Pharma is held by insiders.
Percentage Held by Institutions
Only 28.62% of the stock of Lantern Pharma is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lantern Pharma are expected to grow in the coming year, from ($2.02) to ($1.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lantern Pharma is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lantern Pharma is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lantern Pharma has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Lantern Pharma Stock (NASDAQ:LTRN)

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LTRN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LTRN Stock News Headlines

April 17, 2024 | finance.yahoo.com

Lantern Pharma Inc. (LTRN)

April 13, 2024 | morningstar.com

Lantern Pharma Inc Ordinary Shares

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 10, 2024 | investing.com

Lantern Pharma Inc (LTRN)

March 20, 2024 | seekingalpha.com

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

March 19, 2024 | msn.com

LTRN: 2023 Results

March 19, 2024 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)

March 19, 2024 | finance.yahoo.com

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 18, 2024 | investorplace.com

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023

March 18, 2024 | benzinga.com

Recap: Lantern Pharma Q4 Earnings

March 18, 2024 | finance.yahoo.com

Lantern Pharma Inc Reports Progress and Financials for FY 2023

March 18, 2024 | businesswire.com

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

March 16, 2024 | marketwatch.com

Lantern Pharma Up 20% After Dosing Initiated in Trial for Cancer Drug Developed with AI

March 16, 2024 | finance.yahoo.com

LTRN May 2024 5.000 call

March 16, 2024 | finance.yahoo.com

LTRN Apr 2024 12.500 call

March 15, 2024 | benzinga.com

Lantern Pharma Earnings Preview

March 15, 2024 | finance.yahoo.com

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

March 14, 2024 | finance.yahoo.com

LTRN Mar 2024 10.000 call

March 11, 2024 | businesswire.com

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

March 8, 2024 | finance.yahoo.com

LTRN Oct 2024 5.000 put

March 8, 2024 | finance.yahoo.com

LTRN Apr 2024 2.500 call

March 7, 2024 | finance.yahoo.com

LTRN Mar 2024 7.500 call

March 5, 2024 | finance.yahoo.com

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

March 5, 2024 | businesswire.com

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

March 4, 2024 | finance.yahoo.com

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

February 28, 2024 | msn.com

After Taiwan's striking lantern festival, school kids help clean up the mess

See More Headlines

Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LTRN
CUSIP: N/A
CIK: 1763950
Web: www.lanternpharma.com
Phone: 972-277-1136
Fax: N/A
Employees: 21
Year Founded: 2013

Profitability

EPS (Most Recent Fiscal Year): ($1.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -34.11%
Return on Assets: -32.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.18
Quick Ratio: 16.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.76 per share
Price / Book: 1.44

Miscellaneous

Outstanding Shares: 10,740,000
Free Float: 9,998,000
Market Cap: $58.10 million
Optionable: Optionable
Beta: 1.41

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Panna Sharma PH.D. (Age 53)
President, CEO & Director
Comp: $633.25k
Mr. David R. Margrave (Age 63)
CFO & Secretary
Comp: $394.36k
Dr. Kishor Gopaldas Bhatia Ph.D. (Age 69)
Chief Scientific Officer & Scientific Consultant
Comp: $184.33k
Nicole Leber
Investor Relations Associate, Finance & Administrative Coordinator
Dr. Peter L. Nara D.V.M.
M.S., Ph.D., Co-Founder & Advisor
Mr. Ernest Kitt B.S.
M.S, Head of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LTRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Lantern Pharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LTRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LTRN, but not buy additional shares or sell existing shares.
View LTRN analyst ratings or view top-rated stocks.
How have LTRN shares performed in 2024?: Lantern Pharma's stock was trading at $4.28 at the start of the year. Since then, LTRN stock has increased by 26.6% and is now trading at $5.42.
View the best growth stocks for 2024 here.
Are investors shorting Lantern Pharma?: Lantern Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 420,900 shares, an increase of 191.1% from the March 15th total of 144,600 shares. Based on an average daily volume of 276,000 shares, the short-interest ratio is presently 1.5 days. Currently, 5.3% of the company's shares are sold short.
View Lantern Pharma's Short Interest.
When is Lantern Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LTRN earnings forecast.
How were Lantern Pharma's earnings last quarter?: Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01.
What ETF holds Lantern Pharma's stock?: Horizon Kinetics Medical ETF holds 28,791 shares of LTRN stock, representing 1.31% of its portfolio.

What other stocks do shareholders of Lantern Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK).
When did Lantern Pharma IPO?: Lantern Pharma (LTRN) raised $26 million in an initial public offering on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.
Who are Lantern Pharma's major shareholders?: Lantern Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pathway Financial Advisors LLC (0.23%). Insiders that own company stock include Aaron GL Fletcher and Leslie W Kreis.
View institutional ownership trends.
How do I buy shares of Lantern Pharma?: Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LTRN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lantern Pharma (LTRN) Stock Price, News & Analysis

Lantern Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Lantern Pharma Stock (NASDAQ:LTRN)

LTRN Stock Price History

LTRN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

LTRN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™